About Chiome Bioscience
Chiome Bioscience is a publicly listed company based in Shibuya (Japan) founded in 2010. Antibody-based therapeutics for oncology are developed via ADLib platform. It operates on a HealthTech model. The company has 47 employees. Chiome Bioscience offers products and services including ADLib® System and Drug Discovery Pipeline. Its focus areas include Biotechnology and Biopharmaceuticals. Its legal entity is Chiome Bioscience Inc.
Company details
Chiome Bioscience is focused on drug discovery and development, particularly in the field of biopharmaceuticals. The company is known for its proprietary ADLib System, an antibody creation technology platform. Various therapeutic programs are advanced through its pipeline to address unmet medical needs. Operations are centered in the healthcare sector, with an emphasis on innovative solutions for patients.
- Headquarters Shibuya, Japan
- Employees 47
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website chiome.co.jp
- Social LinkedIn
- Legal Name Chiome Bioscience Inc.
- Annual Revenue$3.79 M (USD)-24.02as on Dec 31, 2025
- Net Profit-$6.27 M (USD)3.72as on Dec 31, 2025
- EBITDA-$6.23 M (USD)5.21as on Dec 31, 2025
- Employee Count47
Products & Services of Chiome Bioscience
Chiome Bioscience offers a comprehensive portfolio of products and services, including ADLib® System and Drug Discovery Pipeline.
Proprietary antibody creation technology is developed and offered.
Pipeline for therapeutic monoclonal antibodies is being advanced.
IPO & Listings of Chiome Bioscience
Chiome Bioscience is a publicly listed company on the TSE with ticker symbol 4583 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Dec 2011
- Listed onTSE: 4583
- Listed entityChiome Bioscience Inc.
- Exchange sectorHealth technology
- ISINJP3205350006
- Share price92.00 JPY (-1.08% on the day) · 2026-10-14
- Market capitalisation7,613,310,699.00 JPY
- EPS (diluted, trailing year)-13.11 JPY
- Volume (last session)569,100
Financials of Chiome Bioscience
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 593.3M JPY | -982.8M JPY | -976.0M JPY |
| 2024 | 780.8M JPY | -1.02B JPY | -1.03B JPY |
| 2023 | 682.5M JPY | -1.22B JPY | -1.20B JPY |
| 2022 | 630.8M JPY | -1.24B JPY | -1.26B JPY |
| 2021 | 712.9M JPY | -1.48B JPY | -1.33B JPY |
Detailed financial statements for Chiome Bioscience
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Chiome Bioscience
The website of Chiome Bioscience (chiome.co.jp) receives about 7.1K visits a month and ranks #2,745,679 among all websites worldwide, #3,703 in Biotechnology and Pharmaceuticals.
- Monthly visits7.1K
▲ 6.6% vs previous month
- Unique visitors2.4K
per month
- Global rank#2,745,679
among all websites
- Category rank#3,703
Health · Biotechnology and Pharmaceuticals
- Bounce rate55%
- Pages per visit2.3
- Average visit33 sec
- DevicesDesktop 52% · Mobile 48%
Websites whose visitors overlap most with Chiome Bioscience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| fujipharma.jp | 100% | 22.9K | #958,114 | View details | |
biotec.co.jp | biotec.co.jp | 96% | #5,862,185 | – | |
phoenixbio.co.jp | phoenixbio.co.jp | 96% | #5,883,984 | – | |
| symbiopharma.com | 93% | 10.1K | #1,553,492 | View details | |
| g-gts.com | 92% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Chiome Bioscience
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chiome Bioscience
Complete news archive for Chiome Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chiome Bioscience
Chiome Bioscience was founded in 2010.
Chiome Bioscience is headquartered in Shibuya, Japan. It is registered at Shibuya, Tokyo, Japan.
Chiome Bioscience has 47 employees.
Annual revenue of Chiome Bioscience is $3.79M as on Dec 31, 2025.
Chiome Bioscience is focused on drug discovery and development, particularly in the field of biopharmaceuticals. The company is known for its proprietary ADLib System, an antibody creation technology platform. Various therapeutic programs are advanced through its pipeline to address unmet medical needs. Operations are centered in the healthcare sector, with an emphasis on innovative solutions for patients.
Chiome Bioscience offers ADLib® System and Drug Discovery Pipeline.
Yes, Chiome Bioscience is publicly traded on TSE under the ticker symbol 4583.
Chiome Bioscience operates through Chiome Bioscience Inc..